Top Story Today
Merck KGaA Bets $11.3 Billion That Selling Picks and Shovels Beats Digging for Gold
Merck KGaA is paying $11.3 billion for Bio-Techne, a life sciences tools company with a vast portfolio of products but essentially flat revenue growth. The 36% premium values Bio-Techne not for what it earns today, but for the sticky, recurring-revenue business model that makes researchers dependent on its reagents, protein platforms, and diagnostics. It's Merck's biggest acquisition since the $17 billion Sigma-Aldrich deal in 2015, and it fires a signal flare across the industry: the infrastructure behind drug development now commands blockbuster valuations, even when top-line growth is stalled.
Why it matters: The deal validates that life science tools and bioprocessing assets are worth premium prices regardless of near-term growth, intensifying the consolidation race among Danaher, Thermo Fisher, and Merck KGaA to build end-to-end research platforms.
Read more →Deals and M&A
Merck KGaA Pays $1.3 Billion to Silence a Gene (Literally)
A 130% premium. An 88% Phase 2 response rate. Merck KGaA is spending $1.3 billion to acquire Silence Therapeutics and its lead siRNA drug divesiran, which reduced therapeutic blood draws in polycythemia vera patients from 2.1 to 0.2. The deal also nets Merck a proprietary gene-silencing platform, a cardiovascular candidate approaching Phase 3, and an AstraZeneca partnership.
Read more →Lilly Bets $1.1 Billion That AI Can Finally Solve Drug Delivery
Eli Lilly committed up to $1.1 billion in milestones and royalties to Hong Kong-based METiS TechBio for its AI-powered nanoparticle design platform. The core problem: RNA therapies overwhelmingly end up in the liver, and METiS claims a library of over 10 million lipids plus AI tools to engineer smarter delivery to other organs. The upfront payment is modest (low double-digit millions), but the signal is loud.
Read more →Beijing Draws a Line Around Its Best Biotech Secrets
China proposed new rules restricting foreign acquisitions of advanced biopharma technologies, including cell and gene therapy platforms and siRNA tools. Licensing deals remain allowed; outright ownership transfers face bans or approval requirements. With $135.7 billion in Chinese outbound biotech deals last year, the message to Western pharma is clear: you can rent, but you can't buy.
Read more →Clinical Wins and Losses
The Cancer That Disappeared in Every Single Patient
GSK's dostarlimab just won FDA accelerated approval for locally advanced MSI-H rectal cancer after the AZUR-1 trial posted a 79% overall response rate by independent central review in 154 patients. For eligible patients, it means potentially beating cancer with immunotherapy alone: no chemo, no radiation, no surgery.
Read more →Tezspire Crashes Dupixent's Party in Eosinophilic Esophagitis
AstraZeneca and Amgen's Tezspire nailed both primary endpoints in a Phase 3 EoE trial, with roughly 65-69% of patients hitting histologic remission versus 3.5% on placebo. The results threaten Dupixent's monopoly as the only approved biologic for the swallowing disorder and could significantly expand Tezspire's peak sales across multiple indications.
Read more →Argenx's Golden Streak Just Snapped
Argenx's Phase 3 Sjogren's disease trial was stopped early for futility, a shock for a company whose FcRn platform had seemed nearly unstoppable. The stock dropped roughly 11-16%. The failure suggests that IgG depletion, which works beautifully in neuromuscular diseases, may not address the more complex immune pathology driving Sjogren's.
Read more →EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips.
After its experimental wet AMD drug DURAVYU missed the primary endpoint in both Phase 3 trials within two months, EyePoint slashed 53% of its workforce and killed both studies. The stock cratered roughly 85% in a single day. The company will redirect remaining cash toward a diabetic macular edema program, but the runway is thin.
Read more →